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Abstract
Background: Ageing has become a worldwide reality and presents new challenges for the health-care system.
Research has shown that potentially inappropriate prescribing, both potentially inappropriate medications and
potentially prescribing omissions, is highly prevalent in older people, especially in the nursing home setting. The
presence of potentially inappropriate medications/potentially prescribing omissions is associated with adverse drug
events, hospitalisations, mortality and health-care costs. The Collaborative approach to Optimise MEdication use for
Older people in Nursing homes (COME-ON) study aims to evaluate the effect of a complex, multifaceted
intervention, including interdisciplinary case conferences, on the appropriateness of prescribing of medicines for
older people in Belgian nursing homes.
Methods/design: A multicentre cluster-controlled trial is set up in 63 Belgian nursing homes (30 intervention;
33 control). In each of these nursing homes, 35 residents (≥65 years) are selected for participation. The complex,
multifaceted intervention comprises (i) health-care professional education and training, (ii) local concertation
(discussion on the appropriate use of at least one medication class at the level of the nursing home) and (iii)
repeated interdisciplinary case conferences between general practitioner, nurse and pharmacist to perform
medication review for each included nursing home resident. The control group works as usual. The study period lasts
15 months. The primary outcome measures relate to the appropriateness of prescribing and are defined as (1) among
residents who had at least one potentially inappropriate medication/potentially prescribing omission at baseline, the
proportion of them for whom there is a decrease of at least one of these potentially inappropriate medications/
potentially prescribing omissions at the end of study, and (2) among all residents, the proportion of them for whom at
least one new potentially inappropriate medication/potentially prescribing omission is present at the end of the study,
compared to baseline. The secondary outcome measures include individual components of appropriateness of
prescribing, medication use, outcomes of the case conferences, clinical outcomes and costs. A process evaluation
(focusing on implementation, causal mechanisms and contextual factors) will be conducted alongside the study.
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Discussion: The COME-ON study will contribute to a growing body of knowledge concerning the effect of complex
interventions on the use of medicines in the nursing home setting, and on factors influencing their effect. The results
will inform policymakers on strategies to implement in the near future.
Trial registration: Current Controlled Trials ISRCTN66138978
Keywords: Inappropriate prescribing, Residential facilities, Aged, Complex intervention, Patient care team,
Interdisciplinary case conferences, Drug-related problems, Medication review, Medication use
Background
Population ageing presents new challenges for the health-
care system [1]; optimising medicines’ prescribing is a major
aspect in this regard [2]. Many studies across different
health-care settings have revealed a high prevalence of
potentially inappropriate prescribing in people aged 65 and
older [3–5]. The term ‘inappropriate prescribing’ encom-
passes three categories: overprescribing, referring to the pre-
scription of a drug without a valid indication; misprescribing,
referring to incorrectly prescribing a drug for a valid indica-
tion; and underprescribing, referring to the failure to pre-
scribe indicated drugs [2]. The presence of inappropriate
prescribing has been associated with adverse drug events
(ADEs) [6], hospitalisations [6–10] and mortality [7].
Over the last years, explicit (criterion-based) and implicit
(judgement-based) tools have been developed to identify
inappropriate prescribing [2]. A European explicit tool that
is currently widely used allows the identification of ‘poten-
tially inappropriate medications’ or PIMs (i.e. events of
overprescribing and misprescribing) on the basis of the
Screening Tool of Older People’s Prescriptions (STOPP)
criteria and ‘potentially prescribing omissions’ or PPOs (i.e.
events of underprescribing) on the basis of the Screening
Tool to Alert to Right Treatment (START) criteria [11]. A
second widely used explicit tool is the American Beers list
[12]. Beers criteria allow identification of PIMs but not
PPOs [12].
The prevalence of inappropriate prescribing is particu-
larly high in nursing homes (NHs). Over the past
10 years, several studies have been conducted to identify
interventions that can increase appropriate prescribing
in this specific setting. Different types of interventions
have been tested: educational approaches; pharmacists’
medication reviews; multidisciplinary team approaches
and the use of computerised decision support systems
(CDSS) [13–18]. These interventions have been tested
separately or in combination. Narrative and systematic
reviews on this topic showed mixed results [13–18]. This
lack of robust conclusions can partly be explained by
variability in the intervention, in the outcomes measured
[14, 17] and in the quality of the studies [18]. Authors’
conclusions in the different reviews are quite similar:
some interventions led to the identification and reso-
lution of drug-related problems (DRPs) [17], but there is
no evidence of an effect of the interventions on resident-
related outcomes, namely ADEs, hospital admissions
and mortality [14, 17, 18] and few or no study assessed
quality of life [17]. Authors suggested that a comprehen-
sive approach, including more than one method to
improve the quality of prescribing, is likely to be re-
quired [13, 15, 18, 19]. As health-care professionals
(HCPs) receive little training in pharmacotherapy in
older people during their basic education, Forsetlund et
al. insisted that any intervention should imply some kind
of education [18]. Currently, the right combination of in-
terventions that can improve the quality of prescribing
in the nursing home setting is not clear. Moreover, as
pointed out by Sanford et al., there is a heterogeneity in
the nursing home characteristics between countries (num-
ber of beds, funding, nursing home residents (NHRs),
trained or untrained staff, visit of physicians,…); hence,
generalisation across countries is limited [20].
As most of the interventions tested were complex and
multifaceted, some authors pointed out the lack of stud-
ies that explored this ‘black box’ effect through a process
evaluation to understand the contribution and impact of
each component [17, 18].
In Belgium, 8.4 % of the 65+ [21] and 42 % of the 85+
live in a NH [22]. Each Belgian NH must appoint a
coordinating physician, who is, together with the head
nurse, responsible for the therapeutic policy of the NH.
Medication-related tasks include organising medication
management in collaboration with pharmacists, develop-
ing and updating the medication formulary, organising
training, etc. Each NHR can choose his/her general prac-
titioner (GP); consequently, the number of visiting GPs
is unrestricted. Furthermore, the GP has a total freedom
of diagnostic and therapeutic strategies, although he is
stimulated to follow the therapeutic policy of the NH.
The delivery of medication is performed by pharmacies,
either hospital pharmacies or community pharmacies. The
NH is in charge of the choice of the delivering pharmacy.
A study conducted in Belgian NHs in 2006 found that
the median number of chronic medications per patient
was 8 (5–10) [22]. Fifty-three percent of residents received
5 to 9 chronic medications daily and 20.8 % had 10 to 14
chronic medications [22]. A particularly high consump-
tion was observed for benzodiazepines and antipsychotics
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(68 %), laxatives (50 %) and antidepressants (46 %) [22]. In
another Belgian study, more than 50 % of NHRs had at
least one drug that could be stopped or modified accord-
ing to the STOPP criteria, while for 30 % of the residents
at least one drug was missing, based on the START
criteria [23].
While policy approaches to improve the quality of drug
prescribing in the nursing home setting have been adopted
in several developed countries such as the USA, UK,
Australia and New Zealand [24], no similar action has yet
been set up in Belgium.
Given the high consumption of medications, the high
prevalence of inappropriate use of medications, and the
lack of structured interdisciplinary approaches in Belgian
NHs, the Belgian National Institute for Health and Disabil-
ity Insurance (NIHDI) launched a national call in 2013.
The objective was to perform a national quality improve-
ment pilot project, aiming at evaluating the effect of inter-
disciplinary collaboration on the appropriateness of use of
medications by NHRs and developing recommendations to
policymakers. This pilot project is the Collaborative ap-
proach to Optimise MEdication use for Older people in
Nursing homes (COME-ON) study described hereafter.
Objectives
The primary objective of the COME-ON study is to evalu-
ate the effectiveness of a complex, multifaceted intervention
on the appropriateness of prescribing for older people in
Belgian NHs. General practitioners, coordinating physi-
cians, nurses and pharmacists are involved in the COME-
ON study. The intervention is built up from a number of
components, mainly training, local concertation and inter-
disciplinary medication reviews during case conferences.
These components may act both independently and inter-
dependently. The intervention can therefore be considered
as a complex intervention [25].
The secondary objectives are to evaluate the effect of the
intervention on medication use, on resident outcomes in
terms of hospital admissions and visits to the emergency
department, and on costs. In addition, a process evaluation
will be conducted to examine the extent to which the inter-
vention is implemented as planned and to explore partici-
pants’ experiences regarding reasons of success or failure,
barriers and facilitators.
The study development was informed by the Medical
Research Council (MRC) guidance for developing and
evaluating complex interventions [25]. The COME-ON
study is built on (a) learning from previous research [15,
17, 18, 26], (b) focus groups with HCPs working in Belgian
NHs to identify their needs with regard to optimization of
medication use, and (c) a pilot study performed in four
NHs spread in the three regions of Belgium. During this
pilot study, the recruitment approach, the adequacy of
research instruments and the feasibility and acceptability
of interdisciplinary medication review were assessed.
Methods/design
Trial design
The COME-ON study is a multicentre, cluster, parallel-
group controlled trial. Each NH represents one cluster. As
the intervention is mainly provided at the level of HCPs, a
cluster design was chosen to prevent contamination bias.
The study design was developed in accordance with the
Consolidated Standards of Reporting Trials (CONSORT)
statement extension to cluster RCTs [27].
Participating nursing homes (clusters)
In the summer of 2013, a national call addressed to all
Belgian NHs was launched by NIHDI. Nursing homes
with at least 35 residents were eligible to participate. For
each NH willing to participate, the management board,
coordinating physician and delivering pharmacist were
asked to complete and sign an application file with
descriptive data relative to the NH, to the residents and
to the local medication management process. Each co-
ordinating physician, pharmacist and management board
could not be involved in more than one application (to
maximise variability in the sample and to prevent con-
tamination bias). In total, 72 NHs applied. After exclu-
sion of duplicates (i.e. two or more applications with the
same pharmacist, the same coordinating physician and/
or the same management board), a final list of 63 NHs
was obtained (Fig. 1).
Allocation
Nursing homes were stratified by (a) province/region, (b)
experience with multidisciplinary case conferences (as
reported in the application file) and (c) type of medication
delivery (by a hospital pharmacy or by one or more com-
munity pharmacies). Factors (b) and (c) were considered
to be possibly significant covariates. Geographical location
(factor a) was taken into account because the funding
body (NIHDI), requested that (i) at least one NH from
each province/region was given the opportunity to imple-
ment the intervention and (ii) the number of NHs
allocated to each group was balanced per province/region.
In 4 of the 10 Belgian regions/provinces, only one NH
applied. These 4 NHs were therefore immediately assigned
to the intervention group. The characteristics of the other
59 NHs with regard to location (province/region), experi-
ence with case conferences and type of delivering phar-
macy, were entered into Statistical Package for the Social
Sciences (SPSS; version 22). This programme generated a
series of blocks for each stratum and allocated NHs to
control or intervention group randomly within each block.
Allocation was performed by an independent researcher
blinded to the identification of the NHs and not involved in
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the recruitment of NHs or residents. Thirty NHs were allo-
cated to the intervention group (as stipulated by NIHDI)
and 33 to the control group. Because of the nature of the
intervention, it was not possible to blind NHs or HCPs to
the intervention.
Nursing homes residents
Residents were considered eligible if they were aged 65 years
or older and were under the care of a participating GP.
Before the study started, the coordinating physician con-
tacted all GPs who had at least one resident in the NH to
ask for their willingness to participate in the study. Resi-
dents receiving palliative care (according to the GP’s evalu-
ation) and residents in subacute care/rehabilitation were
excluded.
Recruitment
In order to have a sufficient (to improve generalisability)
but reasonable (for convenience reasons) number of GPs
involved, all participating GPs caring for at least three
eligible residents were identified. If possible, a maximum
of 12 GPs per NH was aimed for. The objective was to
include 35 residents per NH. One member of the research
team performed resident selection assisted by the head
nurse, the coordinating physician or a representative of
the management board. An algorithm was developed
(available upon request) to support NHR recruitment. If
there were more than 35 eligible residents, a random
selection was made using a statistical software (Statistical
Package for the Social Sciences (SPSS) version 22). Writ-
ten informed consent was asked by physicians (GPs or
coordinating physicians) or nurses to each resident or to a
resident’s representative if the resident was not mentally
competent (e.g. in case of severe dementia). Due to prac-
tical reasons, resident inclusion could not be performed
before group allocation.
Intervention
Based on the evidence that the most successful interven-
tions tend to be interdisciplinary and include more than
one method [15, 17, 18, 26], a multifaceted strategy was
chosen. The key element of this complex intervention is
the structured and repeated interdisciplinary resident’s
medication review (referred to hereafter as ‘interdiscip-
linary case conferences’) supported by training and local
concertation. Each component of the intervention is
described hereafter and in Table 1. The timeline is pro-
vided in Fig. 2. The main components of the complex
intervention have been tested during the pilot phase and
were refined afterwards.
Component 1: education and training
A blended learning programme, combining e-learning
with face-to-face workshops, has been developed. Training
needs and desired formats were discussed during focus
groups with HCPs. The structure of the e-learning plat-
form, the format and content of the blended learning
programme were developed in collaboration with a
team of HCPs and experts in e-learning and geriatric
pharmacotherapy.
The e-learning consists of four modules on the follow-
ing topics: drugs and ageing; (in)appropriate prescribing;
medication review; and team work. Each module takes
approximately 60 min to complete and is built up from a
variety of learning formats including narrative power-
points, videos, serious games, assignments, summary tools
on specific topics and tests. All participating HCPs from
NHs allocated to the intervention group have access to
the e-learning platform that is available during the whole
study duration.
Educational material developed by the research team is
also available through the e-learning platform. It includes
a medication review flowchart, a shortlist of STOPP/
START criteria, and summary sheets on different topics
(e.g. renal function, anticholinergic drugs,…).
Fig. 1 COME-ON study flowchart
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Table 1 Intervention components
Intervention component Description Participants involved Moment and frequency Incentives
Training—e-learning Module 1: Pharmacotherapy in older people; potentially inappropriate
medications and tools used to measure it
Module 2: What is a medication review? How can each health care
professional contribute?
Module 3: How to perform an interdisciplinary medication review?
Module 4: Teamwork
Physicians
Nurses
Pharmacists
Available during
whole study period
Accreditation for GPs and
pharmacists; certificate of
attendance for nurses
Training—onsite workshops Specific training for pharmacists, provided by the research team:
▪ How to prepare a medication review? How to make a suggestion?
Where to find relevant information about medications?
Pharmacists At month 2 Accreditation for pharmacists
Training for all HCPs, provided by the research team:
▪ Problem-based learning using clinical vignettes: How to conduct an
interdisciplinary medication review? What is the contribution of
each HCP? How to classify DRPs?
Physicians
Nurses
Pharmacists
At month 2 Accreditation for GPs and
pharmacists; certificate of
attendance for nurses
Specific training for nurses, provided by the coordinating physician and/or
pharmacist:
▪ Detection of adverse drug events by nurses
▪ Drug administration
Nurses Twice or more during
the study period
Certificate of attendance
Local concertation Discussion about the use of two classes of medications (antidepressants and
lipid-lowering drugs) at the level of the nursing home
Physicians
Nurses
Pharmacists
Twice during the study
(first at month 3 or 4)
Remuneration for all HCPs
involved in the COME-ON
study
Interdisciplinary case conferences Face-to-face medication reviews for each included NHR; duration
approximately 20 min
Physicians
Nurses Pharmacists
Once per 4 months Remuneration for all HCPs
DRP(s) drug-related problem(s), GP(s) general practitioner(s), HCPs health-care professionals, NHR nursing home resident
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Furthermore, the research team moderates two types
of face-to-face interactive workshops (i.e. onsite train-
ing), 2 h each, one specific for pharmacists and one with
all participating HCPs of one or more NHs. The aim is
to apply the theoretical concepts, addressed during the
e-learning, to clinical cases, and to get familiar with
research instruments (DRP classification; web applica-
tion). Specific onsite training for nurses can be given by
the coordinating physician and/or the pharmacist. To
encourage this type of training, preparatory material on
administration of medications and on detection of ADEs
is provided by the research team.
As an incentive, the e-learning modules and onsite work-
shops are accredited for GPs as well as for pharmacists. As
there is currently no similar accreditation programme for
nurses, they receive a certificate of attendance.
Component 2: local concertation
At the level of each participating NH, physicians (GPs
and coordinating physician), pharmacists and nurses are
asked to participate in two ‘local concertation’ meetings.
The objectives of this component are (a) to reach con-
sensus on the appropriate use of one specific class of
medication within each NH, with the intent that this
work could then be used during the interdisciplinary
case conferences and (b) to initiate teamwork and com-
munication between HCPs of the same NH. The overall
output is expected to be (i) a ‘vision’ or a ‘management
plan’ for the treatment of certain condition(s), (ii) a list
of (in)valid indications for the use of the discussed medi-
cations; (iii) a list of molecules to be preferred or
avoided, and underlying reasons and (iv) modalities of
the use of the preferred drugs (e.g. dosage, duration,
follow-up,…). Two medication classes—antidepressants
and lipid-lowering drugs—were selected by the research
team. Material to support the preparation of the meet-
ings and the discussion is provided by the research team.
Each meeting is expected to last approximately 2 h.
The coordinating physician, the pharmacist and the head
nurse are invited to take the lead in preparing, organis-
ing and implementing the meetings (i.e. invitations,
content, discussion, guidelines, overview of figures and
numbers of NHRs taking these medications, summary,
report). Depending on the opportunities and willingness,
additional HCPs can be invited to participate (e.g. geria-
trician, psychiatrist, physiotherapist, occupational ther-
apist). The first meeting has to be held at the beginning
of the study, ideally before the first interdisciplinary case
conferences. A second meeting takes place several months
later. The objective of the latter is to review the imple-
mentation of the consensus reached after the first meet-
ing, to re-discuss or amend this consensus if necessary,
and/or to start the discussion about the second medica-
tion class. The HCPs involved in the study are paid for
their attendance at the meetings.
Component 3: interdisciplinary case conferences
Face-to-face medication reviews have to be conducted for
each NHR included in the study, by an interdisciplinary
team consisting of three HCPs: the GP, the pharmacist,
and a nurse (head nurse, or other nurse involved in the
care of the resident). The medication review focuses on
the appropriate and cost-effective use of all medications
taken by the resident. During the discussion, the team
determines whether drugs must be additionally prescribed,
tapered, discontinued, dose-adjusted, or replaced, and
whether other actions are needed. They are also requested
to prioritise and time schedule the treatment modifica-
tions to be made. Drug-related problems and interven-
tions must be recorded using a DRP classification tool
adapted from Basger et al. [28] and from the PCNE classi-
fication V6.2 [29].
The interdisciplinary case conferences are facilitated
by the use of a web application. This web application
was primarily developed for allowing electronic data
collection (clinical, medical, economic and medication
data). It also enables (i) sharing data about NHRs be-
tween HCPs in the intervention group, allowing prepar-
ation of the medication review by each HCP and (ii)
generating a standardised report of every case confer-
ence, including details on DRPs and interventions, with
the possibility to re-discuss or amend these interventions
at the next meeting.
Fig. 2 Timeline of COME-ON intervention
Anrys et al. Implementation Science  (2016) 11:35 Page 6 of 11
A total of three case conferences per resident over a
12-month period are aimed for. Each case conference is
estimated to last about 20 min. For residents with a
hospital admission during the study period, HCPs are
encouraged to perform an additional medication review
in the fortnight after hospital discharge. For residents
entering end-of-life care, an additional medication re-
view can be conducted with a focus on stopping un-
necessary medications and optimising comfort.
NHRs do not participate in the case conferences.
However, the nurse and the GP are supposed to repre-
sent the interest of the residents by sharing information
on the perception and preferences of the NHRs regard-
ing their current medication regimen. NHRs and/or
their family will be given the opportunity to receive feed-
back from the nurse or the GP on the issues discussed
during the case conferences, and to get information on
the treatment and the proposed changes. HCPs can
agree to postpone the implementation of certain inter-
ventions until discussion with and agreement of the
NHR and/or family. The HCPs are paid for each inter-
disciplinary case conference.
Control group
Nursing homes allocated to the control group receive no
intervention and continue delivering usual care. After
completion of the last data collection, control NHs will
have access to the e-learning platform and will have the
option of attending a symposium that presents a sum-
mary of key messages relative to the effect of the inter-
vention. They will also receive feedback on their own
results relative to appropriateness of prescribing.
Data collection
Data will be collected at three points in time: at month
1 (baseline), month 8 and month 15 (end of study). Data
collection is performed by the HCPs involved in the care
of each resident through a web application. Administra-
tive and clinical data (e.g. age, functional status) are
collected by the nurse, comorbidities (past and current
medical history) and laboratory values by the GP, and
medication data by the pharmacist. In the middle
(month 8) and at the end of the study (month 15), data
on health-care use (hospital admissions, emergency
visits, GP or specialist visits) will also be collected by the
nurse and the GP.
Characteristics of NHs (e.g. number of beds, location)
and administrative data about participating HCPs are
collected at the beginning of the study (month 1) from
the coordinating physician and respective HCPs. HCPs
will be paid for data collection.
In the intervention group, HCPs are also requested to
record data on each case conference (participants, time for
preparation, duration, DRPs identified, interventions,…)
Access to the web application is secured and requires
both the national electronic identity card and the entry
on a list of registered HCPs. HCPs have only access to
data collection files of NHRs for which they are respon-
sible. Data export from the web application to the re-
search database will be performed with the intervention
of a trusted third party (TTP), who is responsible for
data coding and small cell analysis. NHRs and HCPs will
be known to the research team by study ID number
only. The whole process was approved by the Privacy
Commission (nb 14/095, 21/10/2014).
For qualitative data (see ‘Process evaluation’ section),
all interviews and focus groups will be audio recorded
and transcribed verbatim, and the transcripts will be
pseudo-anonymised.
Outcomes
Primary outcome
The primary outcome measures relate to the appropri-
ateness of prescribing at the resident level and are de-
fined as (1) among residents who had at least one PIM/
PPO at baseline, the proportion of them for whom there
is a decrease of at least one of these PIM/PPO at the
end of study and (2) among all residents, the proportion
of them for whom at least one new PIM/PPO is present
at the end of the study as compared to baseline.
PIMs/PPOs will be identified from a pre-defined list of
explicit criteria that includes STOPP/START (version 2)
[11] and Beers (2015) criteria [12]. To automatically
identify PIMs and PPOs from the research database, the
research team has developed and validated with GPs,
geriatricians and pharmacists an algorithm for detecting
STOPP/START criteria (version 2) and Beers criteria
(2015).
Secondary outcome measures
The secondary outcome measures include individual
components of appropriateness of prescribing, medica-
tion use, the outcomes of the case conferences, clinical
outcomes and costs. An overview of secondary outcome
measures is provided in Table 2.
Process evaluation
MRC guidance for complex intervention studies recom-
mends that process evaluations must be conducted within
the trial to assess the implementation of the intervention,
to clarify causal mechanisms and to identify contextual
factors associated with variation in outcomes [30]. These
three aspects (i.e. implementation, causal mechanisms and
contextual factors) will be evaluated during the COME-
ON study (see Table 2). For the implementation evalu-
ation, we will evaluate (1) fidelity, which is the quality of
the implementation, and whether the intervention was
implemented as intended in the protocol; 2) dose, which
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Table 2 Secondary outcome measures and process evaluation
Measure
Secondary outcome measures
Appropriateness of prescribing, individual
components
-Prevalence of PIM and PPO per criterion
Medication use -Number of medications per NHR-Classes of medications used (ATC level 2 and 3)
Clinical outcomes -Death-Hospital admissions-Visits to an emergency department-Visits to the GP and to specialist physicians
Outcomes of case conferences -Type of identified DRPs-Type of planned interventions-Mean/median number of DRPs identified per NHR-Proportion of interventions implemented at
the next case conference
Cost -Cost of medication-Cost of healthcare use (hospital admissions, visits to the emergency department, GP visits, consultation with specialists)-Cost of
intervention
Process evaluation
Training -Dose (number of module per profession,…)-Reach (rate of participation,…)-Experience with intervention (satisfaction survey)
Local concertation -Fidelity (percentage of NHs that organised 2 local concertations,…)-Dose (number of local concertations per NH)-Reach (number of participating GPs
who attended local concertation,…)-Experience with intervention (semi-structured interviews and focus groups)
Interdisciplinary case conferences -Fidelity (percentage of NHRs for which 3 interdisciplinary case conferences were conducted,…)-Dose (median number of case conferences per NHR,…)-
Reach (who attended case conferences,…)-Experience with intervention (semi-structured interviews and focus groups)
Context of the NH -Characteristics of NHs and HCPs-Context in which the intervention is being implemented (semi-structured interviews)
PIM potentially inappropriate medication, PPO potentially prescribing omission, NHR(s) nursing home resident(s), GP general practitioner, NH(s) nursing home(s), DRP(s) drug-related problem(s), HCPs
health-care professionals
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is the number of components of the intervention that was
delivered; and 3) reach, which is the extent to which the
target audience came into contact with the intervention.
A combination of quantitative and qualitative methods
(i.e. mixed-method approach) will be used. The qualita-
tive process evaluation will be conducted through inter-
views or focus groups with a purposive sample of HCPs
to explore their views on the acceptability, effectiveness,
barriers and facilitators of the intervention. Interview
guides will be developed and piloted.
Sample size
Estimations of sample size calculations were performed
for the two primary outcomes.
(1)First, we estimated that among residents who had at
least one PIM/PPO at baseline, there would be a
decrease of at least one of these PIM/PPO at the end
of the study for 20 % of NHRs in the control group
and 40 % in the intervention group. We considered a
power of 80 % and a statistical significance of 5 %. To
take into account, the cluster nature of the study, we
inflated the standard sample size estimates by a factor,
i.e. the design effect = 1 + ρ(m − 1), where m is the
average cluster size and ρ is the estimated intracluster
correlation coefficient (ICC) [31]. As Belgian data on
the ICC for the primary outcome measure were not
available, we made estimations for two extreme
values, i.e. 0.05 and 0.5. In fact, based on what has
been found in the other primary care research setting,
the ICC can be reasonably estimated between 0.05
and 0.5. With an average cluster size of 30 NHRs and
an estimated percentage of dropouts of 22 %, a total of
number of 502 and 3175 NHRs will be required for
ICC values of 0.05 and 0.5, respectively.
(2)Second, we estimated that among all residents,
there would be at least one new PIM/PPO
present at the end of the study as compared to
baseline for 20 % of NHRs in the control group
and 10 % in the intervention group. Similarly to
the estimation for the first outcome, we
considered two extreme values of ICC, i.e. 0.05
and 0.5. With an average cluster size of 30 NHRs
and an estimated percentage of dropouts of 22 %,
a total of number of 1223 and 7738 NHRs will be
required.
As mentioned above, the funding body (NHIDI) deter-
mined a priori the number of NHs and NHRs for the
COME-ON study. Based on the previous cluster studies,
we can expect an ICC closer to 0.05 than 0.5; conse-
quently, a total of approximately 1890 NHRs might be
enough to detect a statistically significant difference.
Data analysis
Quantitative analysis
Data from the trial will be analysed and reported in
accordance with the CONSORT criteria. The baseline char-
acteristics will be reported as mean (± standard deviation)
or median (and P25; P75) values for continuous variables
and as counts (percent) for categorical variables. Descriptive
statistics will be used to evaluate differences between inter-
vention and control group on baseline characteristics at the
resident, physician and nursing home level. Continuous
variables will be compared using Student T test or Wil-
coxon rank-sum test for clustered data, as appropriate.
Categorical variables will be compared using adjusted chi-
square test for clustered data.
To assess the impact of the intervention on the primary
outcomes, logistic regression will take into account the
complex design issues of the study (clustering, stratifica-
tion). A multivariable model will be built to adjust the
analysis for potential confounders, i.e. the number of
PIMs/PPOs at baseline per resident and other baseline
characteristics of residents, GPs and NHs. The analysis
will be conducted using the intent-to-treat analysis, i.e. all
residents will be analysed as randomised. A per protocol
analysis will also be performed as a secondary analysis.
The impact of the complex intervention on the
secondary outcome measures will be assessed using
descriptive data and in some cases, using appropriate
statistical evaluation.
Data analysis will be performed using R software
(Free Software Foundation, Inc., Boston, MA, USA). A
p value <0.05 will be considered statistically significant.
Cost analysis
For the cost analysis, the mean treatment cost over the
study period (from baseline till the end of the study)
will be compared between the residents in the control
and in the intervention group. Treatment costs will be
compared using the independent samples t test for
variables having a normal distribution or the Mann-
Whitney U test for variables not having a normal distri-
bution. These costs will be calculated in 2015 and 2016
values from the perspective of the health-care payer
(NIHDI contribution plus patient co-payment, if applic-
able). Costs will include the costs of the intervention,
the costs of medication and the costs of other health-
care use (GP visits, consultations with specialised
physicians, visits to emergency departments and hospi-
talisations). With respect to the latter, the duration of
hospitalisations will be multiplied by the per diem
hospitalisation prices to generate a proxy estimate of
hospitalisation costs (this excludes hospital costs for
medication, medical imaging and clinical biology, for
which no data will be available) [32].
Anrys et al. Implementation Science  (2016) 11:35 Page 9 of 11
Qualitative analysis
All interviews and/or focus groups will be audio-recorded
and transcribed verbatim. A thematic framework analysis
will be conducted, and facilitated through the use of
NVivo 10.
Ethical approval
The study has been approved by the Ethics Committee
of UZ Leuven on November 12, 2014 (reference number
s57145, ML11035). Furthermore, this study has also
been approved by the Belgian Privacy Commission on
October 21, 2014 (Beraadslaging nr. 14/095, reference:
SCSZ/14/084/174). All included NHRs or residents’ repre-
sentatives provided their written informed consent before
the beginning of the study.
Study registration
This study has been registered at http://www.isrctn.com/
(trial registration number: ISRCTN66138978)
Trial status
Recruitment of NHRs started in January 2015 and was
followed by the baseline data collection in April 2015. The
complex intervention was implemented in NHs from May
2015 onwards, and currently, the second data collection is
ongoing.
Discussion
Articles that have been published in recent years have
highlighted the need to find strategies to optimise the qual-
ity of prescribing in the older population. The COME-ON
study assesses the effectiveness of a complex, multifaceted
intervention on the appropriateness of prescribing in the
nursing home setting.
To our knowledge, this is the first Belgian cluster con-
trolled trial and the largest European trial that assesses a
collaborative approach to optimise medication use in the
nursing home setting.
As recommended in narrative and systematic reviews
on this topic, the strength of this study is the use of a
multifaceted intervention, including different aspects and
comprising an educational part. Moreover, the interven-
tion is supported by a web-application that allows sharing
information between all HCPs involved. The intervention
is also conducted in real-life context; in fact, the interven-
tion relies on HCPs actually working in the nursing home
setting. Thus, if the intervention proves to be effective, it
could be implemented more easily on a wider scale. In the
assessment of a complex intervention, the scope of evalu-
ation should be broader than effectiveness; in fact, policy
makers need information on what works, how and why,
for interpreting the findings and generalising the interven-
tion on a larger scale [30]. This is why a process evaluation
is conducted alongside the study.
There are also potential limitations to this study. First,
the included NHs and participating GPs gave their
agreement to participate in the study; thus, they are per-
haps more concerned about the issue of drug prescribing
for older people. Second, NHRs could only be included
if their treating GP was willing to participate. Third, this
study uses intermediate and process outcome measures
instead of final clinical endpoints.
In conclusion, the COME-ON study will contribute to a
growing body of knowledge concerning the effect of com-
plex interventions on the use of medicines in the NH
setting, and on factors influencing their effect. The results
will inform policymakers on strategies to implement in
the near future.
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